Spinal cord stimulator (SCS) lawsuits are being filed that allege SCS manufacturers (Abbott, Boston Scientific, Medtronic, Nevro) failed to warn of dangers for these products, leading to injuries like internal burns, paralysis, and infection. Over 180,000 adverse reports filed with the FDA indicate high failure rates.
These cases involve allegations that manufacturers:
Injuries linked to spinal stimulators include the following:
The first spinal cord stimulators (SCS) date back to the 1960s to help people with chronic back pain. The device has electrode wires that send low levels of electrical impulses to the spinal cord. A battery implanted under the skin provides the power to the leads.
Since the first SCS was developed by Medtronic in 1968, multiple advances have been made, and additional companies have developed other models. In the 1980s, long-lasting lithium batteries enabled spinal stimulators to become more sophisticated. Modern spinal cord stimulators are divided into three categories:
For individuals who have been diagnosed with an injury linked to use of a spinal cord stimulator, the potential for legal recourse is a critical consideration. Victims may be entitled to financial compensation to cover the following:
Cutaneous T-cell lymphoma (CTCL) is a rare type of skin cancer that affects white blood cells called T lymphocytes. It is a type of non-Hodgkin lymphoma.
Diagnosis
CTCL is diagnosed through a physical exam, skin biopsy, and blood tests.
Treatment
Treatment for CTCL depends on the stage of the disease and the patient’s overall health. Options may include:
Acceleration of cutaneous T-cell lymphoma following dupilumab administration
Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study
Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis
